Tara Baetz

Randomized Comparison of Gemcitabine, Dexamethasone, and Cisplatin Versus Dexamethasone, Cytarabine, and Cisplatin Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed and Refractory Aggressive Lymphomas: NCIC-CTG LY.12

Michael Crump, John Kuruvilla, Stephen Couban et al. · Journal of Clinical Oncology · 2014 · 454 citations · Full text

Randomized Phase II Study of Two Doses of Gefitinib in Hormone-Refractory Prostate Cancer: A Trial of the National Cancer Institute of Canada-Clinical Trials Group

Christina M. Canil, Malcolm J. Moore, Eric Winquist et al. · Journal of Clinical Oncology · 2005 · 207 citations

Gemcitabine, dexamethasone and cisplatin is an active andnon-toxic chemotherapy regimen in relapsed or refractory Hodgkin’s disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group

Tara Baetz, Andrew R. Belch, Stephen Couban et al. · Annals of Oncology · 2003 · 158 citations

National Cancer Institute, Medicine, Pharmacology +9

Phase I Study of ONT-380, a HER2 Inhibitor, in Patients with HER2+-Advanced Solid Tumors, with an Expansion Cohort in HER2+ Metastatic Breast Cancer (MBC)

Stacy L. Moulder, Virginia F. Borges, Tara Baetz et al. · Clinical Cancer Research · 2017 · 155 citations

Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20⁺ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study

Laurie H. Sehn, André Goy, Fritz Offner et al. · Journal of Clinical Oncology · 2015 · 151 citations · Full text